BRPI1010941B1 - Uso de um estabilizador de anel de dinamina - Google Patents

Uso de um estabilizador de anel de dinamina Download PDF

Info

Publication number
BRPI1010941B1
BRPI1010941B1 BRPI1010941-2A BRPI1010941A BRPI1010941B1 BR PI1010941 B1 BRPI1010941 B1 BR PI1010941B1 BR PI1010941 A BRPI1010941 A BR PI1010941A BR PI1010941 B1 BRPI1010941 B1 BR PI1010941B1
Authority
BR
Brazil
Prior art keywords
dynamine
ring
dynamin
actin
stabilizer
Prior art date
Application number
BRPI1010941-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Phillip J. Robinson
Sanja Sever
Original Assignee
Children's Medical Research Institute
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Research Institute, The General Hospital Corporation filed Critical Children's Medical Research Institute
Publication of BRPI1010941A2 publication Critical patent/BRPI1010941A2/pt
Publication of BRPI1010941B1 publication Critical patent/BRPI1010941B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI1010941-2A 2009-05-21 2010-05-21 Uso de um estabilizador de anel de dinamina BRPI1010941B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18026109P 2009-05-21 2009-05-21
US61/180261 2009-05-21
US61/180,261 2009-05-21
PCT/AU2010/000677 WO2010132959A1 (en) 2009-05-21 2010-05-21 Use of dynamin ring stabilizers

Publications (2)

Publication Number Publication Date
BRPI1010941A2 BRPI1010941A2 (pt) 2019-04-09
BRPI1010941B1 true BRPI1010941B1 (pt) 2021-06-22

Family

ID=43125677

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010941-2A BRPI1010941B1 (pt) 2009-05-21 2010-05-21 Uso de um estabilizador de anel de dinamina

Country Status (8)

Country Link
US (1) US8809386B2 (enExample)
EP (1) EP2432465B1 (enExample)
JP (1) JP2012527407A (enExample)
CN (1) CN102481280A (enExample)
AU (1) AU2010251703B2 (enExample)
BR (1) BRPI1010941B1 (enExample)
CA (1) CA2762600C (enExample)
WO (1) WO2010132959A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2782643A1 (en) * 2011-11-23 2014-10-01 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Androgen receptor ligands
WO2014063205A1 (en) * 2012-10-26 2014-05-01 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
JP2017518312A (ja) * 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法
CN105510592A (zh) * 2014-09-26 2016-04-20 中国医学科学院基础医学研究所 梗阻性肾病的蛋白标志物
US11028138B2 (en) * 2016-07-02 2021-06-08 Virongy L.L.C. Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens
CN113801872A (zh) * 2021-10-11 2021-12-17 杭州师范大学 一种精准调控组装制备稳定酶蛋白环的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107736A (en) 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
WO2001064880A2 (en) 2000-02-28 2001-09-07 Millennium Pharmaceuticals, Inc. Human dynamin 40322
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
WO2005049009A1 (en) 2003-11-21 2005-06-02 The University Of Newcastle Research Associates Limited Methods and agents for inhibiting dynamin-dependent endocytosis
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US9144594B2 (en) 2005-11-08 2015-09-29 University Of Miami Cathepsin L mediated diseases and associated methods and products
WO2009034464A2 (en) 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity

Also Published As

Publication number Publication date
EP2432465A1 (en) 2012-03-28
US20120122968A1 (en) 2012-05-17
AU2010251703A1 (en) 2011-12-08
CA2762600C (en) 2018-05-15
US8809386B2 (en) 2014-08-19
EP2432465B1 (en) 2015-07-22
EP2432465A4 (en) 2013-01-02
CA2762600A1 (en) 2010-11-25
AU2010251703B2 (en) 2015-12-24
WO2010132959A1 (en) 2010-11-25
JP2012527407A (ja) 2012-11-08
CN102481280A (zh) 2012-05-30
BRPI1010941A2 (pt) 2019-04-09

Similar Documents

Publication Publication Date Title
EP3021841B1 (en) Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
CA2762600C (en) Use of dynamin ring stabilizers
CN108276490A (zh) 使用BCL-9的安定的α螺旋将癌症中失调WNT信号传递订为目标
Saidjalolov et al. Inclusive Pattern Generation Protocols to Decode Thiol-Mediated Uptake
Lin et al. TFEB agonist clomiphene citrate activates the autophagy-lysosomal pathway and ameliorates Alzheimer's disease symptoms in mice
Rosati et al. Hybrid enzalutamide derivatives with histone deacetylase inhibitor activity decrease heat shock protein 90 and androgen receptor levels and inhibit viability in enzalutamide-resistant C4-2 prostate cancer cells
He et al. GPRC5B protects osteoarthritis by regulation of autophagy signaling
CN103781797A (zh) β转导素重复包含蛋白的结合抑制剂
US9045434B1 (en) Compositions and methods of treatment for myocilin glaucoma by selectively inhibiting GRP94
WO2016120432A1 (en) Compounds and methods for anticoagulation therapy
US20240083951A1 (en) Targeting alpha2delta-1-bound glutamate receptors for treating diseases and disorders
Piacentini et al. Transglutaminase 2 at the crossroads between cell death and survival
CN118453601A (zh) 石蒜碱在制备治疗tdp-43相关疾病的药物中的应用
JP2025522971A (ja) タンパク質様ポリマーを使用するタウの調節及びその使用
Priyanka et al. Native state stabilization of amyloidogenic proteins by kinetic stabilizers: inhibition of protein aggregation and clinical relevance
US20250312332A1 (en) Treatment of muscle fibrosis
JP2013538558A (ja) Ｔｌｒ媒介疾患を治療するためのｔｏｌｌ様受容体（ｔｌｒ）の膜貫通型ドメインに基づくペプチド
US20240327473A1 (en) Tandem repeat protein sequences in protein-like polymers and uses thereof
JP2020172477A (ja) Ｓｔａｔ３非活性化促進化合物及びそのスクリーニング方法
Morello et al. Osteogenesis imperfecta
DK3078372T3 (en) Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor
US20240301386A1 (en) Soluble Guanylyl Cyclase (GC1) Mimetic Polypeptides and Methods of Use Thereof
Pearce Exploring the Heart of MyBP-C.
Barszczyk Caltubin-A Novel Regulator of Neuronal Microtubule Assembly in Mammals
JP2018177685A (ja) 細胞膜の損傷修復促進剤

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25A Requested transfer of rights approved

Owner name: CHILDREN S MEDICAL RESEARCH INSTITUTE (AU)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.